ArticleVaccine2021
NIH funding for vaccine readiness before the COVID-19 pandemic.
Article in Vaccine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 37 citations in OpenAlex.
- Accounting for future populations in health research.Bioethics · 2024Article
- Which roads lead to access? A global landscape of six COVID-19 vaccine innovation models.Globalization and health · 2024Article
- Outlook of pandemic preparedness in a post-COVID-19 world.NPJ vaccines · 2023Review
- US public investment in development of mRNA covid-19 vaccines: retrospective cohort study.BMJ (Clinical research ed.) · 2023Article
- The Lancet Commission on lessons for the future from the COVID-19 pandemic.Lancet (London, England) · 2022Review
- Analyzing the Morality of Owning and Suspending Patent Rights for COVID-19 Vaccines in the Light of Catholic Social Teaching.The Linacre quarterly · 2022Article
- Global COVID-19 Vaccine Inequity: Failures in the First Year of Distribution and Potential Solutions for the Future.Frontiers in public health · 2022Article
- The COVID-19/Tuberculosis Syndemic and Potential Antibody Therapy for TB Based on the Lessons Learnt From the Pandemic.Frontiers in immunology · 2022Review
- Implementation of platform trials in the COVID-19 pandemic: A rapid review.Contemporary clinical trials · 2022Review
- Who funded the research behind the Oxford-AstraZeneca COVID-19 vaccine?BMJ global health · 2021Article
- The hidden influence of communities in collaborative funding of clinical science.Royal Society open science · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapid development of vaccines for COVID-19 has relied on the application of existing vaccine technologies. This work examines the maturity of ten technologies employed in candidate vaccines (as of July 2020) and NIH funding for published research on these technologies from 2000-2019. These technologies vary from established platforms, which have been used successfully in approved products, to emerging technologies with no prior clinical validation. A robust body of published research on vaccine technologies was supported by 16,358 fiscal years of NIH funding totaling $17.2 billion from 2000-2019. During this period, NIH funding for published vaccine research against specific pandemic threats such as coronavirus, Zika, Ebola, and dengue was not sustained. NIH funding contributed substantially to the advance of technologies available for rapid development of COVID-19 vaccines, suggesting the importance of sustained public sector funding for foundational technologies in the rapid response to emerging public health threats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.